Adamis Pharmaceuticals Corp. (ADMP) Sees Strong Trading Volume
Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) saw unusually-strong trading volume on Friday . Approximately 351,876 shares were traded during trading, an increase of 87% from the previous session’s volume of 188,289 shares.The stock last traded at $2.83 and had previously closed at $2.98.
Separately, Maxim Group lowered their price objective on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 21st.
The stock has a 50 day moving average of $3.00 and a 200 day moving average of $5.49. The company’s market capitalization is $42.44 million.
In other news, SVP David J. Marguglio sold 4,860 shares of the business’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $9.17, for a total value of $44,566.20. Following the transaction, the senior vice president now owns 112,227 shares in the company, valued at approximately $1,029,121.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David J. Marguglio sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $8.08, for a total transaction of $32,320.00. Following the completion of the transaction, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The disclosure for this sale can be found here.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.